Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 1Genitourinary 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 378Pituitary Neoplasms 159Multiple Endocrine Neoplasia Type 1 150Thyroid Cancer, Papillary 122Pheochromocytoma 107Carcinoma, Neuroendocrine 93Thyroid Neoplasms 74Paraganglioma 68Carcinoid Tumor 66Neoplasms 54Thyroid Carcinoma, Anaplastic 50Adrenocortical Carcinoma 47Adrenal Gland Neoplasms 46Neoplasm Metastasis 40Insulinoma 39Pancreatic Neoplasms 36Gastro-enteropancreatic neuroendocrine tumor 36Adenoma, Islet Cell 36Carcinoma, Medullary 29Neuroblastoma 28Adenocarcinoma, Follicular 28Hyperaldosteronism 25Prostatic Neoplasms 24Lung Neoplasms 24Obesity 23Brain Neoplasms 22Pituitary Diseases 21Differentiated Thyroid Cancer 20Cushing Syndrome 20Sarcoma 19

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Vascular Neoplasms × Endocrine × Clear all
NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
157 enrolled 26 charts
CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡